Multi-compartmental oral delivery systems for nucleic acid therapy in the gastrointestinal tract

Advanced Drug Delivery Reviews

Volumn 65, Issue 6, 2013, Pages 891-901

  Kriegel, Christina ^a   Attarwala, Husain ^b   Amiji, Mansoor ^c  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b ALNYLAM PHARMACEUTICALS   (United States)

^c NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Gene silencing; Multi compartmental delivery systems; Nucleic acid therapy; Oral gene delivery; Oral small interfering RNA delivery; Transgene expression

Indexed keywords

DELIVERY SYSTEMS; GENE SILENCING; ORAL GENE DELIVERIES; SMALL INTERFERING RNA; TRANSGENE EXPRESSION;

BIOMOLECULES; DISEASE CONTROL; EMULSIFICATION; ENZYME ACTIVITY; GENE TRANSFER; MICROSPHERES; NANOPARTICLES; RNA;

GENE THERAPY;

BETA GALACTOSIDASE; CHITOSAN; CYCLIN D1; DNA VACCINE; ENHANCED GREEN FLUORESCENT PROTEIN; GAMMA INTERFERON; GELATIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GREEN FLUORESCENT PROTEIN; INDIUM 111; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 2; INTERLEUKIN 5; LIPOFECTAMINE; MICROSPHERE; MONOCYTE CHEMOTACTIC PROTEIN 1; NANOPARTICLE; NUCLEIC ACID; PLASMID DNA; POLYCAPROLACTONE; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA; VIRUS VECTOR;

COLITIS; CROHN DISEASE; DOWN REGULATION; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG DESIGN; DRUG DOSAGE FORM COMPARISON; EMULSION; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE SILENCING; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; ISOTOPE LABELING; MOLECULARLY TARGETED THERAPY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RNA INTERFERENCE; SYSTEMIC THERAPY; ULCERATIVE COLITIS; UPREGULATION; VIRAL GENE DELIVERY SYSTEM;

ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; GASTROINTESTINAL TRACT; GELATIN; GENE SILENCING; GENETIC THERAPY; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL ABSORPTION; MICROSPHERES; NANOPARTICLES; NUCLEIC ACIDS; POLYESTERS; RNA, SMALL INTERFERING;

EID: 84878880199     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2012.11.003     Document Type: Review

References (85)

1. Friedmann T. Progress toward human gene therapy. Science 1989, 244:1275-1281.
2. Romano G., Pacilio C., Giordano A. Gene transfer technology in therapy: current applications and future goals. Stem Cells 1999, 17:191-202.
3. Rothman S., Tseng H., Goldfine I. Oral gene therapy: a novel method for the manufacture and delivery of protein drugs. Diabetes Technol. Ther. 2005, 7:549-557.
4. Loretz B., Foeger F., Werle M., Bernkop-Schnuerch A. Oral gene delivery: strategies to improve stability of pDNA towards intestinal digestion. J. Drug Target. 2006, 14:311-319.
5. Lysik M.A., Wu-Pong S. Innovations in oligonucleotide drug delivery. J. Pharm. Sci. 2003, 92:1559-1573.
6. Barquinero J., Eixarch H., Perez-Melgosa M. Retroviral vectors: new applications for an old tool. Gene Ther. 2004, 11:S3-S9.
7. Gao K., Huang L. Nonviral methods for siRNA delivery. Mol. Pharm. 2009, 6:651-658.
8. Glover D.J., Lipps H.J., Jans D.A. Towards safe, non-viral therapeutic gene expression in humans. Nat. Rev. Genet. 2005, 6:299-310.
9. Hollon T. Researchers and regulators reflect on first gene therapy death. Nat. Med. 2000, 6:6.
10. Song S., Morgan M., Ellis T., Poirier A., Chesnut K., Wang J., Brantly M., Muzyczka N., Byrne B.J., Atkinson M., Flotte T.R. Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:14384-14388.
11. Fisher K.J., Jooss K., Alston J., Yang Y., Haecker S.E., High K., Pathak R., Raper S.E., Wilson J.M. Recombinant adeno-associated virus for muscle directed gene therapy. Nat. Med. 1997, 3:306-312.
12. Flotte T.R., Trapnell B.C., Humphries M., Carey B., Calcedo R., Rouhani F., Campbell-Thompson M., Yachnis A.T., Sandhaus R.A., McElvaney N.G., Mueller C., Messina L.M., Wilson J.M., Brantly M., Knop D.R., Ye G.J., Chulay J.D. Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing alpha1-antitrypsin: interim results. Hum. Gene Ther. 2011, 22:1239-1247.
13. Amiji M.M. Polymeric Gene Delivery: Principles and Applications 2005, CRC Press, Boca Raton, FL. M.M. Amiji (Ed.).
14. Alexis F., Pridgen E., Molnar L.K., Farokhzad O.C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm. 2008, 5:505-515.
15. Mathiowitz E., Jacob J.S., Jong Y.S., Carino G.P., Chickering D.E., Chaturvedi P., Santos C.A., Vijayaraghavan K., Montgomery S., Bassett M., Morrell C. Biologically erodable microsphere as potential oral drug delivery system. Nature 1997, 386:410-414.
16. Mansouri S., Lavigne P., Corsi K., Benderdour M., Beaumont E., Fernandes J.C. Chitosan-DNA nanoparticles as non-viral vectors in gene therapy: strategies to improve transfection efficacy. Eur. J. Pharm. Biopharm. 2004, 57:1-8.
17. Dhadwar S.S., Kiernan J., Wen J., Hortelano G. Repeated oral administration of chitosan/DNA nanoparticles delivers functional FVIII with the absence of antibodies in hemophilia A mice. J. Thromb. Haemost. 2010, 8:2743-2750.
18. Plapied L., Vandermeulen G., Vroman B., Preat V., des Rieux A. Bioadhesive nanoparticles of fungal chitosan for oral DNA delivery. Int. J. Pharm. 2010, 398:210-218.
19. Roy K., Mao H.Q., Huang S.K., Leong K.W. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat. Med. 1999, 5:387-391.
20. Chen J., Yang W.L., Li G., Qian J., Xue J.L., Fu S.K., Lu D.R. Transfection of mEpo gene to intestinal epithelium in vivo mediated by oral delivery of chitosan-DNA nanoparticles. World J. Gastroenterol. 2004, 10:112-116.
21. Shim M.S., Kwon Y.J. Efficient and targeted delivery of siRNA in vivo. FEBS J. 2010, 277:4814-4827.
22. Li S.D., Huang L. Gene therapy progress and prospects: non-viral gene therapy by systemic delivery. Gene Ther. 2006, 13:1313-1319.
23. Whitehead K.A., Langer R., Anderson D.G. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 2009, 8:129-138.
24. Akhtar S., Agrawal S. In vivo studies with antisense oligonucleotides. Trends Pharmacol. Sci. 1997, 18:12-18.
25. Roos A.K., Eriksson F., Walters D.C., Pisa P., King A.D. Optimization of skin electroporation in mice to increase tolerability of DNA vaccine delivery to patients. Mol. Ther. 2009, 17:1637-1642.
26. Gothelf A., Eriksen J., Hojman P., Gehl J. Duration and level of transgene expression after gene electrotransfer to skin in mice. Gene Ther. 2010, 17:839-845.
27. Cai X., Conley S., Naash M. Nanoparticle applications in ocular gene therapy. Vision Res. 2008, 48:319-324.
28. de la Fuente M., Ravina M., Paolicelli P., Sanchez A., Seijo B., Alonso M.J. Chitosan-based nanostructures: a delivery platform for ocular therapeutics. Adv. Drug Deliv. Rev. 2010, 62:100-117.
29. Lai S.K., Wang Y.Y., Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv. Drug Deliv. Rev. 2009, 61:158-171.
30. Janat-Amsbury M.M., Yockman J.W., Lee M., Kern S., Furgeson D.Y., Bikram M., Kim S.W. Combination of local, nonviral IL12 gene therapy and systemic paclitaxel treatment in a metastatic breast cancer model. Mol. Ther. 2004, 9:829-836.
31. O'Neill M.J., Bourre L., Melgar S., O'Driscoll C.M. Intestinal delivery of non-viral gene therapeutics: physiological barriers and preclinical models. Drug Discov. Today 2011, 16:203-218.
32. Romano G., Mitcheli P., Pacilio C., Giordano A. Latest developments in gene transfer technology: achievements, perspectives, and controversies over therapeutic applications. Stem Cells 2000, 18:19-39.
33. Prieto J., Herraiz M., Sangro B., Qian C., Mazzolini G., Melero I., Ruiz J. The promise of gene therapy in gastrointestinal and liver diseases. Gut 2003, 52:II49-II54.
34. Dubensky T.W., Liu M.A., Ulmer J.B. Delivery systems for gene-based vaccines. Mol. Med. 2000, 6:723-732.
35. Jones D.H., Corris S., McDonald S., Clegg J.C.S., Farrar G.H. Poly(dl-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. Vaccine 1997, 15:814-817.
36. Howard K.A., Li X.W., Somavarapu S., Singh J., Green N., Atuah K.N., Ozsoy Y., Seymour L.W., Alpar H.O. Formulation of a microparticle carrier for oral polyplex-based DNA vaccines. Biochim. Biophys. Acta, Gen. Subj. 2004, 1674:149-157.
37. Creamer B., Shorter R.G., Bamforth J. Turnover and shedding of epithelial cells .1. Turnover in gastro-intestinal tract. Gut 1961, 2:110.
38. Russell-Jones G.J. Oral vaccine delivery. J. Control. Release 2000, 65:49-54.
39. Fire A., Xu S.Q., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391:806-811.
40. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411:494-498.
41. Sharp P.A. RNA interference-2001. Genes Dev. 2001, 15:485-490.
42. Grimm D., Streetz K.L., Jopling C.L., Storm T.A., Pandey K., Davis C.R., Marion P., Salazar F., Kay M.A. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006, 441:537-541.
43. de Fougerolles A., Vornlocher H.-P., Maraganore J., Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat. Rev. Drug Discov. 2007, 6:443-453.
44. Kim S.-S., Garg H., Joshi A., Manjunath N. Strategies for targeted nonviral delivery of siRNAs in vivo. Trends Mol. Med. 2009, 15:491-500.
45. Aigner A. Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs. J. Biotechnol. 2006, 124:12-25.
46. Aagaard L., Rossi J.J. RNAi therapeutics: principles, prospects and challenges. Adv. Drug Deliv. Rev. 2007, 59:75-86.
47. Zimmermann T.S., Lee A.C.H., Akinc A., Bramlage B., Bumcrot D., Fedoruk M.N., Harborth J., Heyes J.A., Jeffs L.B., John M., Judge A.D., Lam K., McClintock K., Nechev L.V., Palmer L.R., Racie T., Rohl I., Seiffert S., Shanmugam S., Sood V., Soutschek J., Toudjarska I., Wheat A.J., Yaworski E., Zedalis W., Koteliansky V., Manoharan M., Vornlocher H.P., MacLachlan I. RNAi-mediated gene silencing in non-human primates. Nature 2006, 441:111-114.
48. Sato Y., Murase K., Kato J., Kobune M., Sato T., Kawano Y., Takimoto R., Takada K., Miyanishi K., Matsunaga T., Takayama T., Niitsu Y. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat. Biotechnol. 2008, 26:431-442.
49. Park K., Hong S.W., Hur W., Lee M.Y., Yang J.A., Kim S.W., Yoon S.K., Hahn S.K. Target specific systemic delivery of TGF-beta siRNA/(PEI-SS)-g-HA complex for the treatment of liver cirrhosis. Biomaterials 2011, 32:4951-4958.
50. Wang J.P., Feng S.S., Wang S., Chen Z.Y. Evaluation of cationic nanoparticles of biodegradable copolymers as siRNA delivery system for hepatitis B treatment. Int. J. Pharm. 2010, 400:194-200.
51. Milner J. RNA interference for treating cancers caused by viral infection. Expert Opin. Biol. Ther. 2003, 3:459-467.
52. Chen X.Z., Zhu K.J., Xu Y., Tang X.Y., Cai X.Z., Zhang X., Cheng H. RNA interference silences the human papillomavirus 6b/11 early gene E7 in vitro and in vivo. Clin. Exp. Dermatol. 2010, 35:509-515.
53. Landen C.N., Merritt W.M., Mangala L.S., Sanguino A.M., Bucana C., Lu C., Lin Y.G., Han L.Y., Kamat A.A., Schmandt R., Coleman R.L., Gershenson D.M., Lopez-Berestein G., Sood A.K. Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biol. Ther. 2006, 5:1708-1713.
54. Mangala L.S., Han H.D., Lopez-Berestein G., Sood A.K. Liposomal siRNA for ovarian cancer. Methods Mol. Biol. 2009, 555:29-42.
55. Kriegel C., Amiji M. Oral TNF-alpha gene silencing using a polymeric microsphere-based delivery system for the treatment of inflammatory bowel disease. J. Control. Release 2011, 150:77-86.
56. Kriegel C., Amiji M. Dual TNF-α/Cyclin D1 gene silencing with an oral polymeric microparticle system as a novel strategy for the treatment of inflammatory bowel disease. Clin. Transl. Gastroenterol. 2011, 2:1-12.
57. Akhtar S., Benter I.F. Nonviral delivery of synthetic siRNAs in vivo. J. Clin. Invest. 2007, 117:3623-3632.
58. Jackson A.L., Linsley P.S. Noise amidst the silence: off-target effects of siRNAs?. Trends Genet. 2004, 20:521-524.
59. Bartlett D.W., Davis M.E. Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res. 2006, 34:322-333.
60. Sorensen D.R., Leirdal M., Sioud M. Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J. Mol. Biol. 2003, 327:761-766.
61. Kortylewski M., Swiderski P., Herrmann A., Wang L., Kowolik C., Kujawski M., Lee H., Scuto A., Liu Y., Yang C., Deng J., Soifer H.S., Raubitschek A., Forman S., Rossi J.J., Pardoll D.M., Jove R., Yu H. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat. Biotechnol. 2009, 27:925-U988.
62. Choi B., Hwang Y., Kwon H.J., Lee E.-S., Park K.S., Bang D., Lee S., Sohn S. Tumor necrosis factor alpha small interfering RNA decreases herpes simplex virus-induced inflammation in a mouse model. J. Dermatol. Sci. 2008, 52:87-97.
63. Peer D., Park E.J., Morishita Y., Carman C.V., Shimaoka M. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science 2008, 319:627-630.
64. Grzelinski M., Urban-Klein B., Martens T., Lamszus K., Bakowsky U., Hobel S., Czubayko F., Aigner A. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum. Gene Ther. 2006, 17:751-766.
65. Aouadi M., Tesz G.J., Nicoloro S.M., Wang M., Chouinard M., Soto E., Ostroff G.R., Czech M.P. Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature 2009, 458:1180-1184.
66. Dass C.R., Choong P.F.M. Chitosan-mediated orally delivered nucleic acids: a gutful of gene therapy. J. Drug Target. 2008, 16:257-261.
67. Pouton C.W., Seymour L.W. Key issues in non-viral gene delivery. Adv. Drug Deliv. Rev. 2001, 46:187-203.
68. Attarwala H., Amiji M. Multi-compartmental nanoparticles-in-emulsion formulation for macrophage-specific anti-inflammatory gene delivery. Pharm. Res. 2012, 29(6):1637-1649.
69. K.M., M. Amiji, S., Jain, H., Attarwala, MULTI-COMPARTMENTAL MACROPHAGE DELIVERY, in, WO Patent WO/2011/119,881, 2011.
70. Jain S., Amiji M. Tuftsin-modified alginate nanoparticles as a noncondensing macrophage-targeted DNA delivery system. Biomacromolecules 2012, 13(4):1074-1085.
71. Bhavsar M.D., Tiwari S.B., Amiji M.M. Formulation optimization for the nanoparticles-in-microsphere hybrid oral delivery system using factorial design. J. Control. Release 2006, 110:422-430.
72. Bhavsar M.D., Amiji M.M. Oral IL-10 gene delivery in a microsphere-based formulation for local transfection and therapeutic efficacy in inflammatory bowel disease. Gene Ther. 2008, 15:1200-1209.
73. Bhavsar M.D., Amiji M.M. Development of novel biodegradable polymeric nanoparticles-in-microsphere formulation for local plasmid DNA delivery in the gastrointestinal tract. AAPS PharmSciTech 2008, 9:288-294.
74. Bhavsar M.D., Amiji M.M. Gastrointestinal distribution and in vivo gene transfection studies with nanoparticles-in-microsphere oral system (NiMOS). J. Control. Release 2007, 119:339-348.
75. Shahiwala A., Amiji M.M. Enhanced mucosal and systemic immune response with squalane oil-containing multiple emulsions upon intranasal and oral administration in mice. J. Drug Target. 2008, 16:302-310.
76. Bouma G., Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol. 2003, 3:521-533.
77. Strober W., Fuss I., Mannon P. The fundamental basis of inflammatory bowel disease. J. Clin. Invest. 2007, 117:514-521.
78. Papa A., Mocci G., Bonizzi M., Felice C., Andrisani G., Papa G., Gasbarrini A. Biological therapies for inflammatory bowel disease: controversies and future options. Expert Rev. Clin. Pharmacol. 2009, 2:391-403.
79. Hoentjen F., Van Bodegraven A.A. Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease. World J. Gastroenterol. 2009, 15:2067-2073.
80. Armuzzi A., De Pascalis B., Lupascu A., Fedeli P., Leo D., Mentella M.C., Vincenti F., Melina D., Gasbarrini G., Pola P., Gasbarrini A. Infliximab in the treatment of steroid-dependent ulcerative colitis. Eur. Rev. Med. Pharmacol. Sci. 2004, 8:231-233.
81. Fu M., Wang C., Li Z., Sakamaki T., Pestell R. Minireview: cyclin D1: normal and abnormal functions. Endocrinology 2004, 145:5439-5447.
82. Alao J.P., Gamble S.C., Stavropoulou A.V., Pomeranz K.M., Lam E.W.F., Coombes R.C., Vigushin D.M. The cyclin D1 proto-oncogene is sequestered in the cytoplasm of mammalian cancer cell lines. Mol. Cancer 2006, 5.
83. Alao J.P. The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol. Cancer 2007, 6.
84. Kornmann M., Ishiwata T., Arber N., Beger H.G., Korc M. Increased cyclin D1 expression in chronic pancreatitis. Pancreas 1998, 17:158-162.
85. Kommareddy S., Amiji M. Poly(ethylene glycol)-modified thiolated gelatin nanoparticles for glutathione-responsive intracellular DNA delivery. Nanomedicine 2007, 3:32-42.